businesspress24.com - Medgenics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
 

Medgenics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

ID: 1456227

(firmenpresse) - PHILADELPHIA, PA -- (Marketwired) -- 09/06/16 -- (NYSE MKT: MDGN) today announced that Michael F. Cola, President and Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference in New York, NY on Monday, September 12, 2016 at 9:10 a.m. EDT at the Lotte New York Palace Hotel.

A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company''s website at or you may use the link:



Medgenics is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. Medgenics is also the developer of TARGT™ (Transduced Autologous Restorative Gene Therapy), a proprietary gene therapy platform.

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company''s financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company''s assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company''s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.







Medgenics
Brian Piper
240-899-5554


Westwicke Partners
Chris Brinzey
339-970-2843

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Theravance Biopharma Announces New Employment Inducement Awards
Pharma-Bio Third-Quarter 2016 Update: $5.8 Billion Investment in Project Starts Reflects Good Health of the Industry, an Industrial Info News Alert
Bereitgestellt von Benutzer: Marketwired
Datum: 06.09.2016 - 06:00 Uhr
Sprache: Deutsch
News-ID 1456227
Anzahl Zeichen: 3360

contact information:
Contact person:
Town:

PHILADELPHIA, PA


Phone:

Kategorie:

Biotech


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 216 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Medgenics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von

Medgenics, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Medgenics, Inc.



 

Who is online

All members: 10 563
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 107


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.